Accepted Manuscript

Pricing and Reimbursement of Generic Pharmaceuticals in Turkey: Evaluation of Hypertension Drugs From 2007 to 2013

Seda KUMRU, Mehmet TOP

 PII:
 S2211-8837(18)30090-X

 DOI:
 10.1016/j.hlpt.2018.03.004

 Reference:
 HLPT 284

To appear in:

Health Policy and Technology

Received date:24 October 2017Revised date:9 March 2018Accepted date:13 March 2018

Please cite this article as: Seda KUMRU, Mehmet TOP, Pricing and Reimbursement of Generic Pharmaceuticals in Turkey: Evaluation of Hypertension Drugs From 2007 to 2013, *Health Policy and Technology* (2018), doi: 10.1016/j.hlpt.2018.03.004

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



HIGHLIGHTS

- Generic drugs which are equivalent to the original drugs and are allowing access to the same medical outcomes at lower costs often play a part of drug expenditure control policies.
- Between 2007 and 2012, while consumption of prescribed drugs in the hypertension group increased about 63%, hypertension drug expenditures of SSI increased almost 82% in Turkey
- This results showed that the pricing and reimbursement policies for generic drugs need to change, especially internal reference pricing system should be redesigned in Turkey.
- The results of this study can provide important benefits for drug economy studies in Turkey. The pharmaceutical economy in Turkey is a discipline that is beginning to develop.

Chillip Martin

Download English Version:

https://daneshyari.com/en/article/8733121

Download Persian Version:

https://daneshyari.com/article/8733121

Daneshyari.com